Hims & Hers: A Strategic Overhaul Tested by Margins and Market Sentiment

The stock of telehealth provider Hims & Hers has been under significant pressure, trading roughly 40 percent below its level at the start of the year. This decline follows a forced and fundamental business model shift that has reshaped the company’s profit profile and triggered a wave of skepticism from both Wall Street and its own largest shareholders.

The catalyst was a regulatory chain reaction beginning in early 2026. The U.S. Food and Drug Administration classified the company’s compounded weight-loss medications as “unapproved,” followed by a patent infringement lawsuit from Novo Nordisk. Faced with this pressure, Hims & Hers reached a settlement in March: it ceased selling its compounded pills and instead became a distribution partner for Novo Nordisk’s branded drug, Wegovy. While resolving legal uncertainty, this pivot carries substantial economic consequences, moving the firm from a high-margin manufacturer to a lower-margin distributor.

Analysts at Bank of America have adjusted their forecasts accordingly, maintaining a Neutral rating but lowering their price target to $21 from $23. They estimate 2026 EBITDA could land about 20 percent below market consensus, with the contribution from GLP-1 weight-loss drugs potentially shrinking by up to 50 percent year-over-year. A central concern is customer conversion; BofA models that 40 to 50 percent of existing subscribers will switch to the $149-per-month Wegovy plan, with another 5 to 10 percent staying on compounded offerings, yielding quarterly GLP-1 revenue between $60 million and $90 million.

The market’s caution is visibly reflected in recent trading activity. The stock is currently consolidating in a range between $19 and $20, with a near-term support level at its 30-day low of $18.62 and resistance around $22.80. More tellingly, prominent institutional and insider selling has emerged. Major investor Carnegie Investment Counsel slashed its position by nearly 70 percent, leaving a stake worth around $3 million. On the management side, Chief Operating Officer Michael Chi sold shares worth approximately $2.4 million, while insider Irene Becklund divested almost 40 percent of her holdings. Over the past three months, executives have liquidated close to 130,000 shares in total.

Should investors sell immediately? Or is it worth buying Hims & Hers?

This selling underscores doubts about future profitability. The company’s gross margin, which soared above 80 percent during the peak of the compounding business, had already fallen to 72 percent in Q4 2025. Management now expects it to stabilize in the low-70 percent range for 2026—a level typical of a pharmacy distributor. Additional competitive pressure comes from Amazon Pharmacy, which announced it would offer Eli Lilly’s newly approved oral GLP-1 drug, Foundayo, with same-day delivery at an identical $149 monthly price for cash-paying customers.

Despite the headwinds, some analysts see potential for a rebound. The stock’s valuation, at a price-to-sales multiple of just 2.0 based on trailing revenue of $2.35 billion, sits well below its historical median of 3.3. A return to that median would imply a share price above $30. Canaccord analyst Maria Ripps reaffirmed a Buy rating, viewing the Novo Nordisk partnership as a long-term tailwind. Barclays recently raised its price target to $29, citing reduced legal overhang. Needham argues demand for Wegovy pills through direct-to-consumer channels is underestimated.

Upcoming events will be critical for the new strategy. The company reports first-quarter results in early May 2026, with consensus expecting earnings of $0.03 per share. This report will provide the first concrete data on subscriber conversion rates. Furthermore, the pending $1.15 billion acquisition of Australian telehealth firm Eucalyptus, slated for completion by mid-2026, represents a major opportunity. It is central to the company’s goal of generating over $1 billion in international revenue within three years, potentially reducing its reliance on the volatile U.S. weight-loss market.

The path forward hinges on proving that its reconfigured business can drive growth even with slimmer margins, while successfully integrating a major acquisition to diversify its revenue base.